<DOC>
	<DOCNO>NCT00027807</DOCNO>
	<brief_summary>RATIONALE : Biological therapy use different way stimulate immune system stop cancer cell grow . Combining different type biological therapy may kill tumor cell . PURPOSE : Phase I/II trial study effectiveness combine different biological therapy treat woman stage IV breast cancer .</brief_summary>
	<brief_title>Biological Therapy Treating Women With Stage IV Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine maximum tolerate dose arm activated T cell give combination interleukin-2 sargramostim ( GM-CSF ) woman stage IV breast cancer . - Determine toxicity profile regimen patient . - Determine clinical response overall progression-free survival patient treat regimen . OUTLINE : This dose-escalation study arm activated T cell . Patients undergo peripheral blood mononuclear cell ( PBMC ) collection . The PBMCs treat ex vivo monoclonal antibody OKT3 form arm activated T cell ( ATC ) . The armed ATC expand 14 day interleukin-2 ( IL-2 ) . Patients receive arm ATC IV 30 minute twice weekly 4 week . Patients also receive IL-2 subcutaneously ( SC ) daily sargramostim ( GM-CSF ) SC twice weekly begin 3 day first infusion arm ATC continue 7 day last infusion arm ATC . Cohorts 3-6 patient receive escalate dos arm ATC maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . Once MTD determine , additional patient treat dose . Patients follow 1 , 2 , 5 month every 6 month thereafter . PROJECTED ACCRUAL : A total 15-30 patient accrued phase I portion study total 18-33 patient accrue phase II portion study within 4-6 year . PLEASE NOTE : THIS STUDY WAS INTENDED TO BE A PHASE I/II STUDY , BUT NEVER MOVED FORWARD TO PHASE II . ( 4-22-09 )</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Aldesleukin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Phase I : Histologically confirm infiltrating ductal carcinoma breast Metastatic disease Clinically asymptomatic nonlifethreatening metastasis allow Measurable evaluable disease radiograph , CT scan , MRI , nuclear medicine bone scan , physical examination No measurable disease allow tumor metastasis remove successfully treat prior study No rapidly progressive symptomatic disease affect major organ system ( e.g. , lung liver ) Stable unstable disease 3 month hormonal therapy Stable unstable disease least 1 month chemotherapy No active brain metastasis Brain metastasis previously treat definitive radiotherapy and/or surgical resection allow Hormone receptor status : Estrogen progesterone receptor status know Phase II : All Phase I criteria HER2/neu overexpression ( 2+ 3+ ) immunohistochemistry Prior trastuzumab ( Herceptin ) allow disease still overexpresses HER2/neu PATIENT CHARACTERISTICS : Age : 18 Sex : Female Menopausal status : Not specify Performance status : Karnofsky 70100 % OR ECOG 02 Life expectancy : At least 3 month Hematopoietic : Granulocyte count least 1,500/mm^3 Platelet count least 50,000/mm^3 Hemoglobin least 8 g/dL Hepatic : Bilirubin le 1.5 time normal SGOT le 1.5 time normal Renal : Creatinine great 1.8 mg/dL Creatinine clearance least 60 mL/min BUN great 1.5 time normal Cardiovascular : No myocardial infarction within past year No prior myocardial infarction coronary symptom require medication and/or depress leave ventricular function ( LVEF less 50 % MUGA ) No angina coronary symptom require medication and/or depress leave ventricular function ( LVEF less 50 % MUGA ) No congestive heart failure require medical management LVEF least 50 % rest MUGA No uncontrolled hypertension ( i.e. , systolic blood pressure [ BP ] ≥ 130 mm Hg diastolic BP ≥ 80 mm Hg ) Pulmonary : FEV1 , DLCO , FVC least 50 % predict Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception HIV negative No serious medical psychiatric illness would preclude study participation No prior concurrent malignancy within past 5 year except curatively treat squamous cell carcinoma situ cervix , basal cell skin cancer , curatively treated disease complete remission PRIOR CONCURRENT THERAPY : Biologic therapy : See Disease Characteristics Prior trastuzumab allow phase I Chemotherapy : See Disease Characteristics At least 4 week since prior chemotherapy Endocrine therapy : See Disease Characteristics Concurrent hormonal therapy breast cancer must continue study No concurrent hormonal therapy except steroid adrenal failure , septic shock , pulmonary toxicity hormonal therapy nondiseaserelated condition ( e.g. , insulin diabetes ) Radiotherapy : See Disease Characteristics Surgery : See Disease Characteristics</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>stage IV breast cancer</keyword>
	<keyword>recurrent breast cancer</keyword>
	<keyword>ductal breast carcinoma</keyword>
</DOC>